

# Addressing Gaps in MS Patient Care Via Personalized Continuing Education

Katie Robinson, PhD<sup>1</sup>; Patricia Coyle, MD<sup>2</sup>; and Robert A. Esgro<sup>1</sup>

<sup>1</sup>Vindico Medical Education, Thorofare, NJ, krobinson@VindicoCME.com, <sup>2</sup>Stony Brook University Medical Center, Stony Brook, NY

## 1 Defining the Need for Education

### At the time of the needs assessment (Jan '17)



- There was a 5-year period of rapid approvals for RRMS; providers struggled to differentiate options<sup>1-2</sup>
- No therapies were available for PPMS<sup>1</sup>
- Shared decision making (SDM) was underutilized<sup>2-3</sup>

### Identified Knowledge/Competence Gaps to Define the Educational Needs




#### Immunopathology of Disease and Associated Implications

- Neurology providers scored only 44% on questions related to the immunopathology disease and associated clinical implications (e.g., diagnosis, classes of therapies)<sup>2</sup>



#### Clinical Advances & Patient Engagement

- Neurology providers scored only 35% on pretest questions related to current and emerging treatment options; 37% lacked confidence in differentiating treatment options<sup>2</sup>
- 97% of neurologists recognize the importance of SDM, yet 40% of patients with MS report they have no say in treatment<sup>2,3</sup>



1. D'Amico E, et al. *Int J Mol Sci*. 2016;17:1-14.  
2. Vindico Data on File. *Neurology*. 2016-2017.  
3. Wray S, et al. *Neurology*. 2015;84(suppl): abstr P3.235.



## 2 Program Content and Design

### Program Goals and Content


Optimize use of new guidelines and patient outcomes via sequential, personalized education on



### Personalized Learning Approach



### Follow-up Participants



## 4 Overall Impact of the Education

### Educational Efficacy

Overall there was an **48%** relative increase in knowledge and competence

**60%** relative increase in knowledge regarding frequency of MRI use in patients on DMTs

**78%** posttest score on questions related to MS in pregnancy

**56%** relative increase in knowledge regarding current and emerging DMTs

### Potential Patient Impact




**>3.8K** Number of patients with MS seen per month who are **32% more likely to receive evidence-based care**


## 5 Personalized Learning – Impact of the Education

**100%** Noted that the personalized learning activities reinforced the original content from MS Forum or the web enduring

### Impact on Knowledge



### Posttest scores of those who scored 0% on initial CME posttest



Q: What are options for 30-y/o newly diagnosed patient?

A: IFNβ GA, DMF, fingolimod, teriflunomide, or ocrelizumab

Q: Which of the following is true regarding pregnancy in MS?

A: Pregnancy is safe for women with MS, with no increased risk of complications

Q: What is the best management plan for a 61-y/o with SPMS?

A: Ocrelizumab plus exercise therapy


### Self-Reported Performance

**100%** Of personalized learning participants have implemented practice changes N=15


This activity was supported by educational grants from Novartis Pharmaceuticals Corporation; Sanofi Genzyme; and Teva Pharmaceuticals.

## 3 Overall Demographics

### Degree



### Specialty




**78%** Were physicians, APPs, or nurses

**60%** Specialize in neurology, radiology or nursing

Providers see on average **8 patients per month** with MS

## 6 Conclusions & Opportunities

### Personalized Education



- ✓ Addresses persisting knowledge gaps
- ✓ Encourages follow-up participation
- ✓ Gathers participation beyond that which was directly targeted

### Opportunities

- ✓ Direct targeting of personalized education can be adopted across specialties
- ✓ Personalized learning can be adopted for sequential delivery of education or customization of educational curricula